53rd ICAAC, September 10-13, 2013, Denver CO

Conference Reports for NATAP


53rd ICAAC September 10-13, 2013 Denver CO

	HIV at ICAAC PrEP 2103 - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (09/20/13) HIV at ICAAC "Mother-To-Child Transmission" 2013 - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (09/20/13) HIV at ICAAC "HIV Cure" 2013 Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (09/20/13) HIV at ICAAC Comorbidities 2013 - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (09/20/13) HIV at ICAAC TAF 2013 - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (09/20/13) HIV at ICAAC Dolutegravir 2013 - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (09/20/13) Dolutegravir, New Integrase Inhibitor; GSK744 PrEP/ART Every 3 Months Faster Bone Turnover With Atripla Than With Dolutegravir/ABC/3TC in 48 Weeks - Written by Mark Mascolini - (09/16/13) 48 Week Bone Marker Changes in Dolutegravir (DTG; GSK1349572) Plus Abacavir/Lamivudine (ABC/3TC) vs Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): The SINGLE Trial - (09/13/13) Good Safety Profile With Long-Acting Integrase Inhibitor, GSK744 - Written by Mark Mascolini - (09/11/13) Dolutegravir Superior to Darunavir at 48 Weeks in Open-Label ART-Naive Trial (The FLAMINGO Study) - Written by Mark Mascolini - (09/14/13) Meta-analysis of Safety Data From 8 Clinical Studies With GSK1265744, an HIV Integrase Inhibitor, Dosed Orally or as Injection of Long-Acting Parenteral Nanosuspension (LAP) - (09/12/13) Dolutegravir in Key Demographic Subgroups of Treatment-Experienced HIV-Infected Populations - (09/16/13) Bioequivalence of a Dolutegravir, Abacavir and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food - (09/16/13) Pharmacokinetics (PK) and Safety of Dolutegravir (DTG) in Subjects With Severe Renal Impairment and Healthy Controls - (09/16/13) Pharmacokinetics (PK) and PK-Pharmacodynamic (PD) Relationship of Dolutegravir (DTG) in Integrase Inhibitor (INI)-Naive Subjects - (09/16/13) Raltegravir, New NNRTI MK1439 Ritonavir Boosts Levels of MK-1439, a New Nonnucleoside--TDF Has No Impact - Written by Mark Mascolini - (09/17/13) Raltegravir Safe for Pregnant Women and Their Newborns in 31-Case Study - Written by Mark Mascolini - (09/16/13) Efficacy and Safety of Raltegravir Among Latin American Patients in STARTMRK - (09/16/13) Raltegravir Top PIs and NNRTIs in Retrospective Look at Cancer Patients - Written by Mark Mascolini - (09/14/13) TAF, Tenofovir, PrEP, Elvitegravir, Rilpivirine Studies Lack of Clinically Relevant Drug Interactions Between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Telaprevir - (09/12/13) Long-Term Tolerability of Elvitegravir/cobicistat/emtricitabine/tenofovir DF Compared to Efavirenz/emtricitabine/tenofovir DF or Ritonavir-Boosted Atazanavir Plus Emtricitabine/tenofovir DF in Treatment-Naive HIV-1-Infected Subjects - (09/12/13) Status of Truvada (TVD) for HIV Pre-Exposure Prophylaxis (PrEP) in the United States: An Early Drug Utilization Analysis - (09/12/13) Tenofovir Intravaginal Ring - (09/24/13) ICAAC: Pigtailed Macaques Under High Doses of Depot Medroxyprogesterone are Protected from Multiple SHIV Exposures with a Tenofovir Disoproxil Fumarate Intravaginal Ring - (09/24/13) Novel Mutation Combinations Linked to Resistance to Rilpivirine - Written by Mark Mascolini - (09/11/13) TAF Comparable to TDF in Once-Daily Pill for ART-Naive: 48-Week Results - Written by Mark Mascolini - (09/14/13) 48 Week Study of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF), Each in a Single Tablet Regimen (STR) with Elvitegravir, Cobicistat, and Emtricitabine [E/C/F/TAF vs. E/C/F/TDF] for Initial HIV Treatment - (09/16/13) Tenofovir Vaginal Ring Protects 5 of 6 Macaques From SHIV After High-Dose Depo-Provera - Written by Mark Mascolini - (09/18/13) Lack of Effect of Tenofovir Alafenamide (TAF) on Primary Osteoblasts In Vitro at Clinically Relevant Drug Concentrations - (09/12/13) TAF, a Tenofovir Prodrug, Not Preferentially Loaded or Toxic in Osteoblasts - Written by Mark Mascolini - (09/11/13) Complera Not Inferior to Atripla Among Men and Women in 786-Person Trial - Written by Mark Mascolini - (09/12/13) Stribild and Comparison Combinations Have Similar Efficacy in Over-50s and Under-50s - Written by Mark Mascolini - (09/14/13) Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Demonstrates Comparable Efficacy and Favorable Tolerability to Efavirenz/Emtricitabine/Tenofovir DF and to Ritonavir-boosted Atazanavir Plus Emtricitabine/Tenofovir DF in Patients ≥50 Years at Week 96 - (09/16/13) SPIRIT: Simplifying to Rilpivirine/Emtricitabine/Tenofovir DF Single-Tablet Regimen from Boosted Protease Inhibitor Regimen Maintains HIV Suppression in the Black Subgroup Week 48 Results - (09/16/13) Single-Pill Rilpivirine Regimen Maintains Suppression After Switch From Boosted PI - Written by Mark Mascolini - (09/11/13) Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) has Durable Efficacy and Differentiated Long-Term Safety and Tolerability Versus Efavirenz/Emtricitabine/Tenofovir DF (ATR) at Week 144 in Treatment-Naïve HIV Patients - (09/16/13) STaR: Virologic Outcomes and Safety in ART-Naïve Adult Females for Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Compared to Efavirenz/Emtricitabine/Tenofovir DF at Week 48 - (09/16/13) Multicentre Open-Label Study of Switching from Atripla to Eviplera for Possible Efavirenz Associated CNS Toxicity* - (09/16/13) Switching From Efavirenz to Rilpivirine Combo Quells CNS Side Effects - Written by Mark Mascolini - (09/11/13) Switch from efavirenz/emtricitabine/tenofovir DF to elvitegravir/cobicistat/emtricitabine/tenofovir DF: Efficacy and Pharmacokinetics - (09/12/13) Tricky Pharmacokinetics May Not Matter in Switch From Efavirenz to Stribild - Written by Mark Mascolini - (09/11/13) Combinations of HIV-1 Reverse Transcriptase Mutations L100I+K103N/S and L100I+K103R+V179D Reduce Susceptibility to Rilpivirine - (09/18/13) Almost Half of Early US PrEP Are Women, Often in Southern States - Written by Mark Mascolini - (09/11/13) Safety Analysis Gives Edge to Elvitegravir vs Efavirenz or Atazanavir at 96 Weeks - Written by Mark Mascolini - (09/11/13) Tumor Characteristics and Survival in HIV-Infected Patients with Hepatocellular Carcinoma: the Impact of Surveillance - (10/02/13) Efficacy and Safety of Rilpivirine-Based Regimens in Treatment-Experienced HIV-1 Infected Patients: A Prospective Cohort Study - (09/31/13) Acute C hepatitis in Japanese HIV-infected patients in this decade - (09/31/13) Worse Response to PegIFN/RBV for HCV After Transplant in HIV/HCV+ vs HCV+ - Written by Mark Mascolini - (09/18/13) Valacyclovir Has No Impact on CD4s or HIV Load in Placebo Trial of HSV-2+ - Written by Mark Mascolini - (09/18/13) Once-Daily Darunavir/Ritonavir (DRV/r) Versus Atazanavir/Ritonavir (ATV/r) on Insulin Sensitivity in HIV-Infected Persons Over 48 Weeks - (09/18/13) CLINICAL CHARACTERIZATION OF HIV/HCV CO-INFECTED PATIENTS TREATED WITH DIRECT ACTING ANTIVIRAL AGENTS - (09/18/13) Identifying High Responder Populations to Crofelemer for Treatment of Noninfectious Diarrhea in HIV+ Individuals - (09/17/13) Single-Tablet Regimen More Effective Impact of HAART Regimen on Adherence and Risk of Hospitalization in HIV/AIDS Patients Using VA Data - (09/17/13) HIV Does Not Affect Chance of HCV Genotype 2 or 3 Responding to PegIFN/RBV - Written by Mark Mascolini - (09/17/13) Adherence Better, In-Hospital Rate Lower With Single-Tablet ART in US Veterans - Written by Mark Mascolini - (09/16/13) SVR Tied to Lower Progression, Mortality in HIV/HCV+ With Moderate Fibrosis - the importance of treating coinfected patients - Written by Mark Mascolini - (09/16/13) Host Immune Environment Significantly Impact the Level of CD4 Reconstitution and the Effects on Latent Reservoir in HIV Subjects Receiving ZFN CCR5 Modified CD4 T-cells (SB-728-T) - (09/16/13) Host Immune Environment Significantly Impact the Level of CD4 Reconstitution and the Effects on Latent Reservoir in HIV Subjects Receiving ZFN CCR5 Modified CD4 T-cells (SB-728-T) - (09/16/13) Sangamo BioSciences announces presentation of clinical Data Demonstrating Functional Control of Viremia in HIV-Infected Subjects treated with SB-728-T - (09/16/13) Functional Control of Viremiain CCR5-Δ32 Heterozygous (Δ32HZ) HIV+ Subjects Following Adoptive Transfer of Zinc Finger Nuclease CCR5 Modified AutologousCD4 T-cells (SB-728-T) - (09/16/13) Simplification to Abacavir/Lamivudine (ABC/3TC) + Atazanavir (ATV) From Tenofovir/Emtricitabine (TDF/FTC) + ATV/Ritonavir (r) Maintains Viral Suppression and Improves Bone Biomarkers: 48 Week ASSURE - (09/16/13) Similar Cognition Outcomes After 48 Weeks for Tenofovir (TDF)/Emtricitabine (FTC) + Atazanavir/Ritonavir (ATV/r)-Experienced HIV+ Patients or Those Simplifying to Abacavir (ABC)/Lamivudine (3TC) + ATV - (09/16/13) Fosamprenavir/Ritonavir (FPV/r) in Hepatically Impaired Subjects: An Observational Multi-Cohort Study - (09/16/13) Strong Correlation Between The Reduction Of Cellular HIV-DNA Load And Achievement Of HIV Plasma Viremia<2.5 Copies/ml In An Observation Period Of 4 Years Of Effective Antiretroviral Therapy In Naïve Patients - (09/16/13) Hepatitis C Eradication Reduces Liver Decompensation, HIV progression, and Death in HIV/HCV-coinfected Patients with non-Advanced Liver Fibrosis - (09/12/13) Low Aspirin or Statin Use for Primary MI/Stroke Prevention at HIV Clinic - Written by Mark Mascolini - (09/14/13) Low Aspirin or Statin Use for Primary MI/Stroke Prevention at HIV Clinic - Written by Mark Mascolini - (09/14/13) One in 5 HIV+ Women in Spanish Group Has Anal Dysplasia, Predicted by Warts - Written by Mark Mascolini - (09/14/13) Routine Vaccination Rates Highly Variable in French Adults With HIV - Written by Mark Mascolini - (09/14/13) Adverse Event Rates Similar With High-Dose ATV/r and LPV/r During Pregnancy - Written by Mark Mascolini - (09/14/13) Second- and Third-Line ART Cost 24% and 41% More Than First Line in US - Written by Mark Mascolini - (09/14/13) Darunavir and Atazanavir Have Similar Modest Impact on Insulin Sensitivity - Written by Mark Mascolini - (09/14/13) Ritonavir Boosts Levels of MK-1439, a New Nonnucleoside--TDF Has No Impact - Written by Mark Mascolini - (09/14/13) HPV-39 Predicts AIN and Anal Cancer in Spanish Group of Men With HIV - Written by Mark Mascolini - (09/14/13) Erectile Dysfunction Drug Use Doubles Odds of Syphilis in US Men With HIV - Written by Mark Mascolini - (09/12/13) Crofelemer Effective for Severe or PI-Related Diarrhea in Placebo Trial - Written by Mark Mascolini - (09/12/13) Status of Truvada (TVD) for HIV Pre-Exposure Prophylaxis (PrEP) in the United States: An Early Drug Utilization Analysis - (09/12/13) Burden of Illness in a US Commercially Insured HIV Population: Treatment Patterns and Costs - (09/12/13) Second- and Third-Line ART Cost 24% and 41% More Than First Line in US - Written by Mark Mascolini - (09/11/13) Cellular HIV DNA Predicts Plasma Load Under 2.5 Copies in 181-Person Study - Written by Mark Mascolini - (09/11/13) TDF/FTC-to-ABC/3TC Switch Maintains Viral Suppression, Eases Bone Markers - Written by Mark Mascolini - (09/11/13) Good Results With No-NRTI Strategy in ART Experienced: Small Retrospective Study - Written by Mark Mascolini - (10/16/13) Worse Response to PegIFN/RBV for HCV After Transplant in HIV/HCV+ vs HCV+ - Written by Mark Mascolini - (09/20/13) Nearly 10% Screened for Syphilis Test Positive at California HIV Clinic - Written by Mark Mascolini - (09/20/13) Almost Half of Pneumocystis Patients in France Already in HIV Care at PCP Diagnosis - Written by Mark Mascolini - (09/20/13)